In the News
Sulfonylureas not supported as second-line treatment for type 2 diabetes
Risk for major adverse cardiovascular events and all-cause mortality was higher when a sulfonylurea was added to metformin compared to other typical second- or third-line therapy options in a recent Danish study.
Diabetes-related variables, general comorbidities may predict major osteoporotic fractures
A study of African-American, Hispanic, and Caucasian patients with type 1 and type 2 diabetes found that the most significant predictors of fracture risk varied by race and ethnicity.
Type 2 diabetes, elevated glucose associated with increased risk of unspecified dementia
Risk of Alzheimer's disease or vascular dementia was not associated with nonfasting plasma glucose levels in a large Danish study that included patients with and without diabetes.
MKSAP quiz: Fracture risk
This month's quiz asks readers to evaluate a 38-year-old woman with antiphospholipid syndrome, recurrent diffuse alveolar hemorrhage, and secondary diabetes mellitus who is taking prednisone.
Spotlight on glycemic variability
Recent research quantified the association between visit-to-visit variability in HbA1c levels and risk of cardiovascular disease and death.
Cyclical pressurized topical wound oxygen therapy increased healing of refractory diabetic foot ulcers
An industry-funded randomized trial showed that topical wound oxygen therapy is efficacious, but more data on effectiveness, outcomes, and cost are needed, an ACP Journal Club commentary said.
SGLT-2 inhibitor-associated ketoacidosis—a history lesson
In a new Annals On Call podcast, host Robert M. Centor, MD, MACP, analyzes ketoacidosis associated with sodium-glucose cotransporter-2 (SGLT-2) inhibitors with guest Bruce R. Leslie, MD, FACP.
1 in 10 older inpatients with diabetes discharged with intensified medication regimen
Nearly half of those who had their diabetes medications intensified after hospitalization had already reached outpatient blood glucose goals or had limited life expectancy, according to a recent Veterans Health Administration study.
Insulin, other biologics gain new pathway for biosimilars
The FDA expects that the regulatory transition, mandated by Congress, will support market competition and increase patient access to these drugs.